9月1日，翔港科技涨5.22%，截至发稿，报20.16元/股，成交4.04亿元，换手率6.78%，总市值61.00亿 元。 资料显示，上海翔港包装科技股份有限公司位于中国(上海)自由贸易试验区临港新片区泥城镇翠波路 299号，成立日期2006年8月30日，上市日期2017年10月16日，公司主营业务涉及彩盒、标签等相关包装 印刷产品的研发、生产和销售。主营业务收入构成为：包装印刷50.39%，包装容器38.33%，化妆品 7.98%，租赁2.49%，劳务0.48%，其他0.33%。 从基金十大重仓股角度 数据显示，广发基金旗下1只基金重仓翔港科技。广发鑫和混合A（004750）二季度持有股数12.57万 股，占基金净值比例为0.21%，位居第九大重仓股。根据测算，今日浮盈赚取约12.57万元。 广发鑫和混合A（004750）成立日期2018年1月16日，最新规模1.71亿。今年以来收益3.43%，同类排名 7160/8254；近一年收益7.52%，同类排名7224/8037；成立以来收益51.63%。 广发鑫和混合A（004750）基金经理为吴迪。 截至发稿，吴迪累计任职时间5年119天，现任基金资产总规模7 ...

Group 1 - The stock price of Zhongtung High-tech has increased by 5.17% on September 1, reaching 21.75 CNY per share, with a trading volume of 2.163 billion CNY and a turnover rate of 8.16%, resulting in a total market capitalization of 49.567 billion CNY [1] - Zhongtung High-tech's stock has risen for six consecutive days, with a cumulative increase of 13.56% during this period [1] - The company specializes in the research, development, production, sales, and trade of hard alloys and rare metals such as tungsten, molybdenum, tantalum, and niobium, with its main business revenue composition being: 34.74% from ore and powder products, 23.13% from other hard alloys, 21.68% from cutting tools, 16.23% from refractory metals, and 4.22% from trade and equipment [1] Group 2 - According to data from the top ten heavy stocks of funds, one fund under Guotai Fund has a significant holding in Zhongtung High-tech. The Guotai Jinlong Industry Select Mixed Fund (020003) held 2.4285 million shares in the second quarter, accounting for 3.45% of the fund's net value, making it the third-largest heavy stock [2] - The floating profit from the stock during the six-day increase is approximately 599.84 thousand CNY, with a current floating profit of about 259.85 thousand CNY [2] - The Guotai Jinlong Industry Select Mixed Fund (020003) has a total asset scale of 834 million CNY, with a year-to-date return of 20.28% and a one-year return of 49.65% [2]

Core Viewpoint - Huaxia Airlines experienced a stock price decline of 2.07% on September 1, with a current price of 9.01 CNY per share and a total market capitalization of 11.517 billion CNY [1] Financial Performance - For the first half of 2025, Huaxia Airlines reported operating revenue of 3.610 billion CNY, representing a year-on-year increase of 12.41% [2] - The net profit attributable to shareholders for the same period was 251 million CNY, showing a significant year-on-year growth of 858.95% [2] Stock and Shareholder Information - As of June 30, 2025, the number of shareholders for Huaxia Airlines was 22,200, a decrease of 14.08% from the previous period [2] - The average number of circulating shares per shareholder increased by 16.38% to 57,578 shares [2] - Since its A-share listing, Huaxia Airlines has distributed a total of 209 million CNY in dividends, with no dividends paid in the last three years [3] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included several funds, with Zhonggeng Value Pioneer Stock (012930) holding 42.2532 million shares, a decrease of 9.2025 million shares from the previous period [3] - Other notable shareholders included Guangfa Value Leading Mixed A (008099) and Guangfa Ruiyi Leading Mixed A (005233), with stable holdings [3]

Company Overview - Huaxi Biological Technology Co., Ltd. is located in Jinan, Shandong Province, established on January 3, 2000, and listed on November 6, 2019. The company specializes in microbial fermentation and cross-linking technology platforms, developing bioactive materials that benefit human health. It has established a full industry chain from raw materials to medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing companies, medical institutions, and end-users [2]. Financial Performance - As of July 31, the number of Huaxi Biological shareholders reached 32,500, an increase of 1.78% from the previous period. The average circulating shares per person decreased by 1.75% to 14,799 shares [2]. - For the first half of 2025, Huaxi Biological reported operating revenue of 2.261 billion yuan, a year-on-year decrease of 19.57%. The net profit attributable to the parent company was 221 million yuan, down 35.38% year-on-year [2]. Stock Performance - Huaxi Biological's stock price has increased by 14.59% year-to-date, with a 1.81% rise over the last five trading days, a 13.65% increase over the last 20 days, and a 6.69% increase over the last 60 days [2]. - On September 1, the stock price rose by 2.03%, reaching 58.36 yuan per share, with a trading volume of 246 million yuan and a turnover rate of 0.89%. The total market capitalization stood at 28.111 billion yuan [1]. Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders included various ETFs, with notable changes in holdings. For instance, Huaxia SSE Sci-Tech Innovation Board 50 ETF held 10.6429 million shares, down 244,800 shares from the previous period. Meanwhile, the E Fund SSE Sci-Tech Innovation Board 50 ETF increased its holdings by 227,800 shares to 7.9777 million shares [3].

Group 1 - The core viewpoint of the news is that BGI Tech (华大九天) has seen a significant stock price increase of 6.1%, reaching 130.50 CNY per share, with a trading volume of 1.232 billion CNY and a market capitalization of 70.854 billion CNY [1] - BGI Tech, established on May 26, 2009, and listed on July 29, 2022, specializes in the development and sales of EDA tools for integrated circuit design and manufacturing, with 82.57% of its revenue coming from EDA software sales, 13.41% from technical services, and 4.02% from hardware and other sales [1] Group 2 - From the perspective of fund holdings, Huian Fund has a significant position in BGI Tech, with its Huian Trend Power Stock A fund holding 20,000 shares, accounting for 3.8% of the fund's net value, making it the ninth largest holding [2] - The Huian Trend Power Stock A fund, established on April 25, 2018, has a current scale of 6.8521 million CNY, with a year-to-date return of 23.62% and a one-year return of 44.85% [2]

分红方面，欣旺达A股上市后累计派现16.61亿元。近三年，累计派现6.45亿元。 责任编辑：小浪快报 资料显示，欣旺达电子股份有限公司位于广东省深圳市宝安区石岩街道石龙社区颐和路2号综合楼,香港 铜锣湾希慎道33号利园1期19楼1919室，成立日期1997年12月9日，上市日期2011年4月21日，公司主营 业务涉及锂离子电池模组的研发、设计、生产及销售。 欣旺达所属申万行业为：电力设备-电池-锂电池。所属概念板块包括：智能音箱、电动物流车、无线耳 机、电子烟、基金重仓等。 截至6月30日，欣旺达股东户数11.46万，较上期增加5.76%；人均流通股14946股，较上期减少5.45%。 2025年1月-6月，欣旺达实现营业收入269.85亿元，同比增长12.82%；归母净利润8.56亿元，同比增长 3.88%。 9月1日，欣旺达盘中上涨2.04%，截至11:24，报25.05元/股，成交22.03亿元，换手率5.24%，总市值 462.37亿元。 资金流向方面，主力资金净流出2832.20万元，特大单买入1.88亿元，占比8.53%，卖出2.27亿元，占比 10.30%；大单买入6.01亿元，占比27.26% ...

Core Viewpoint - Guangdong Hongda's stock price has shown a significant increase of 34.06% year-to-date, with recent fluctuations indicating a slight decline in the short term [1][2]. Financial Performance - For the first half of 2025, Guangdong Hongda achieved a revenue of 9.15 billion yuan, representing a year-on-year growth of 65.64%, while the net profit attributable to shareholders was 504 million yuan, up 22.05% year-on-year [2]. - The company has distributed a total of 2.097 billion yuan in dividends since its A-share listing, with 1.137 billion yuan distributed over the past three years [3]. Stock Market Activity - As of September 1, Guangdong Hongda's stock price was 34.90 yuan per share, with a market capitalization of 26.524 billion yuan. The stock experienced a trading volume of 174 million yuan and a turnover rate of 0.76% [1]. - The net inflow of main funds was 6.3666 million yuan, with large orders accounting for 26.77% of purchases and 18.10% of sales [1]. Shareholder Structure - As of August 20, the number of shareholders for Guangdong Hongda increased to 36,700, a rise of 10.97%, while the average circulating shares per person decreased by 9.88% to 17,977 shares [2]. - Notable new institutional shareholders include Fu Guo Tian Hui Growth Mixed Fund and Guangfa Small Cap Growth Mixed Fund, which have entered the top ten circulating shareholders [3].

Company Overview - Bid Pharma is located in Yangpu District, Shanghai, and was established on April 27, 2007. The company went public on October 11, 2022. Its main business focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [1][2]. Financial Performance - For the first half of 2025, Bid Pharma achieved a revenue of 628 million yuan, representing a year-on-year growth of 17.91%. The net profit attributable to shareholders was 73.41 million yuan, showing a year-on-year increase of 41.60% [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. Stock Performance - As of September 1, Bid Pharma's stock price increased by 2.34%, reaching 68.68 yuan per share, with a total market capitalization of 6.242 billion yuan. The stock has risen by 42.19% year-to-date, with a 2.25% increase over the last five trading days, 14.95% over the last 20 days, and 48.18% over the last 60 days [1]. - The stock's trading volume on September 1 was 61.0887 million yuan, with a turnover rate of 2.11% [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 3,782, a rise of 4.76%. The average number of circulating shares per person decreased by 4.55% to 11,431 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by China Europe Medical Health Mixed A and an increase by Agricultural Bank of China Medical Health Stock [3].

资料显示，中际旭创股份有限公司位于山东省龙口市诸由观镇驻地，成立日期2005年6月27日，上市日 期2012年4月10日，公司主营业务涉及电机定子绕组制造装备的研发、设计、制造、销售与服务;光模块 设备制造。主营业务收入构成为：光通信模块97.58%，汽车电子1.74%，光组件0.67%。 9月1日，中际旭创涨5.23%，截至发稿，报373.50元/股，成交91.05亿元，换手率2.19%，总市值4150.03 亿元。 浙商汇金先进制造混合（013145）基金经理为王霆。 截至发稿，王霆累计任职时间6年93天，现任基金资产总规模3560.5万元，任职期间最佳基金回报 23.12%， 任职期间最差基金回报6.09%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，浙商证券资管旗下1只基金重仓中际旭创。浙商汇金先进制造混合（013145）二季度持有股 数8600股，占基金净值比例为3.52%，位居第五大重仓股。根据测算，今 ...

Company Overview - Optoelectronics Technology Co., Ltd. is located in Dongguan, Guangdong Province, established on March 24, 2006, and listed on December 31, 2020. The company primarily engages in the research, development, production, and sales of core hardware and software products for machine vision [1][2]. Financial Performance - For the first half of 2025, Optoelectronics achieved operating revenue of 683 million yuan, representing a year-on-year growth of 30.68%. The net profit attributable to shareholders was 146 million yuan, reflecting a year-on-year increase of 28.80% [2]. - Since its A-share listing, Optoelectronics has distributed a total of 392 million yuan in dividends, with 215 million yuan distributed over the past three years [3]. Stock Performance - As of September 1, Optoelectronics' stock price decreased by 2.05%, trading at 140.65 yuan per share, with a total market capitalization of 17.192 billion yuan. The stock has increased by 86.63% year-to-date, with a 7.21% rise over the last five trading days, 38.14% over the last 20 days, and 60.10% over the last 60 days [1]. - The company has seen a net outflow of 11.81 million yuan in principal funds, with significant buying and selling activity from large orders [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders was 6,005, a decrease of 13.18% from the previous period. The average number of circulating shares per person increased by 15.19% to 20,355 shares [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by the Fuguo Tianhui Growth Mixed Fund and the entry of the Huaxia CSI Robot ETF as a new shareholder [3]. Industry Classification - Optoelectronics is classified under the mechanical equipment sector, specifically in the automation equipment category, and is associated with concepts such as holography, neural networks, and Huawei-related themes [2].